We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced positive interim data from a phase III study on its duchenne muscular dystrophy (DMD) candidate,casimersen. Data from the ESSENCE study showed that treatment with casimersen led to statistically significant mean increase of dystrophin protein production (as measured by western blot) compared to baseline and placebo.
DMD is a genetic disorder caused by a mutation that prevents the body from producing dystrophin, a protein that muscles need to function properly. Casimersen works through a method called exon skipping, which helps the body's cellular machinery make functional dystrophin. Sarepta already has a marketed drug, Exondys 51 in its portfolio, which is the first approved disease-modifying therapy for DMD in the United States.
In the past year, the company’s shares have increased 60.2% against the industry’s decline of 13.9%.
In the study, 22 patients receiving casimersen displayed an increase in skipping exon 45 over their baseline levels, representing a 100% response rate. The company plans to submit a new drug application (NDA) to the FDA in mid-2019, after holding apre-NDA meeting with the agency.
Sarepta is looking to build its DMD pipeline beyond Exondys 51 by developing other exon-skipping treatments. In fact, the company has about 13 exon-skipping candidates in its pipeline, the most advanced ones being golodirsen and casimersen. In December 2018, the company completed a rolling NDA submission, seeking accelerated approval for golodirsen. A decision is expected by Aug 19, 2019.
The company expects to double the eligible DMD patient population for its marketed products in 2020 compared to 2018, on potential approval of golodirsen and casimersen.
Other companies also involved in developing DMD therapies include Catabasis Pharmaceuticals, Inc. , Summit, PTC Therapeutics, Pfizer Inc. (PFE - Free Report) , BioMarin (BMRN - Free Report) et al.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced positive interim data from a phase III study on its duchenne muscular dystrophy (DMD) candidate,casimersen. Data from the ESSENCE study showed that treatment with casimersen led to statistically significant mean increase of dystrophin protein production (as measured by western blot) compared to baseline and placebo.
DMD is a genetic disorder caused by a mutation that prevents the body from producing dystrophin, a protein that muscles need to function properly. Casimersen works through a method called exon skipping, which helps the body's cellular machinery make functional dystrophin. Sarepta already has a marketed drug, Exondys 51 in its portfolio, which is the first approved disease-modifying therapy for DMD in the United States.
In the past year, the company’s shares have increased 60.2% against the industry’s decline of 13.9%.
In the study, 22 patients receiving casimersen displayed an increase in skipping exon 45 over their baseline levels, representing a 100% response rate. The company plans to submit a new drug application (NDA) to the FDA in mid-2019, after holding apre-NDA meeting with the agency.
Sarepta is looking to build its DMD pipeline beyond Exondys 51 by developing other exon-skipping treatments. In fact, the company has about 13 exon-skipping candidates in its pipeline, the most advanced ones being golodirsen and casimersen. In December 2018, the company completed a rolling NDA submission, seeking accelerated approval for golodirsen. A decision is expected by Aug 19, 2019.
The company expects to double the eligible DMD patient population for its marketed products in 2020 compared to 2018, on potential approval of golodirsen and casimersen.
Other companies also involved in developing DMD therapies include Catabasis Pharmaceuticals, Inc. , Summit, PTC Therapeutics, Pfizer Inc. (PFE - Free Report) , BioMarin (BMRN - Free Report) et al.
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. Price | Sarepta Therapeutics, Inc. Quote
Zacks Rank
Sarepta currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>